HAE Stock Analysis: Buy, Sell, or Hold?
HAE - Haemonetics Corporation
$54.93
0.89 (1.65%)
▲
5d:
-6.04%
30d:
-13.25%
90d:
-31.58%
HOLD
LOW Confidence
Analysis Updated: Mar 30, 2026 12:00 AM ET
Earnings: May 14, 2026
Get Alerted When HAE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: HAE shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: HAE shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$93.09
Based on 5.8% avg growth
INTRINSIC VALUE TODAY
$57.80
5.0% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 13.2x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: HAE is currently trading at $54.93, which is considered oversold relative to its 30-day fair value range of $57.79 to $63.51. From a valuation perspective, the stock is trading at a discount (Forward PE: 10.3) compared to its historical average (13.2). Remarkably, the market is currently pricing in an annual earnings decline of 7.9% over the next few years. This pessimistic expectation contrasts with the company's recent 28.4% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, HAE is in a strong downtrend. The price is currently testing key support at $53.88. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $87.50 (+59.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, HAE is in a strong downtrend. The price is currently testing key support at $53.88. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $87.50 (+59.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$57.79 -
$63.51
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
79.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 59.3% below Wall St target ($87.50)
- CAUTION: Recommendation downgraded due to -6.0% 5-day decline
Fair Price Analysis
30-Day Fair Range
$57.79 -
$63.51
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$53.88
Resistance Level
$60.93
Current Trend
Strong Downtrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
10.32
Wall Street Target
$87.50
(+59.3%)
Revenue Growth (YoY)
-2.7%
Earnings Growth (YoY)
28.4%
Profit Margin
13.3%
Valuation Discount vs History
-7.9% cheaper
PE vs Historical
10.3 vs 13.2
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-7.9%
(market-implied from PE analysis)
1-Year Target
$50.59
(-8%)
2-Year Target
$46.59
(-15%)
3-Year Target
$42.91
(-22%)
3-Yr Target (if PE normalizes)
(PE: 10→13)
$54.88
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.4, Growth: 7.6%)
$148.11
(+170%)
Base:
(SPY PE: 10.3, Growth: 7.6%)
$68.40
(+25%)
Bear:
(PE: 8.8, Growth: 7.6%)
$58.14
(+6%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (16x PE), but valuation improves significantly next year (10x PE) as earnings recover.
Trailing PE: 16.14 | Current EPS (TTM): $3.63
Bull Case
$94.47
(+62%)
Analyst growth 46.6%, PE expands to 17.8
Base Case
$85.88
(+47%)
Market implied 46.6%, PE stable at 16.1
Bear Case
$39.83
(-32%)
Severe decline -20.0%, PE contracts to 13.7
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 10.3 to 13.2
Stabilization Target:
$70.25
(+27.9%)
PE Expansion Potential:
+27.9%
Share & Embed Analysis
Last updated: March 31, 2026 2:10 AM ET
Data refreshes hourly during market hours. Next update: 3:10 AM
Data refreshes hourly during market hours. Next update: 3:10 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is HAE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$102 | 60 HOLD |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$424 | 56 HOLD |
|
DXCM
DexCom Inc |
STRONG BUY
26 analysts |
$86 | 51 HOLD |
|
ABT
Abbott Laboratories |
BUY
28 analysts |
$133 | 61 BUY |
|
PODD
Insulet Corporation |
STRONG BUY
23 analysts |
$354 | 48 HOLD |
